We use cookies to ensure that we give you the best experience on our website Learn more

Apr 1, 2016

26th European Congress of Clinical Microbiology and Infectious Diseases

Low rates of severe injection-site and systemic adverse events within 7 days post-vaccination with ZOSTAVAX™, a post hoc analysis of two pivotal phase 3 trials

;

Zoran Popmihajlov;

Lei Pang;

Elizabeth Brown;

Shu-Chih Su;

Susan Kaplan;

English Willis

zoster vaccine live

shingles vaccine

zostavax

herpes zoster

vaccine

thumbnail

Keywords

zoster vaccine live

shingles vaccine

zostavax

herpes zoster

vaccine

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.